StreetInsider.com News Articles

Form 4 Emergent BioSolutions For: Jun 08 Filed by: Williams Paul Anthony

Wed, 10 Jun 2026 15:09:00 -0400

si-local-file:///var/storage/secattach/20260610/26629503.html

Form 4 Emergent BioSolutions For: Jun 08 Filed by: Williams Paul Anthony

Wed, 10 Jun 2026 15:09:00 -0400

si-local-file:///var/storage/secattach/20260610/26629503.html

Form 4 Emergent BioSolutions For: Jun 08 Filed by: LINDAHL RICHARD S

Wed, 10 Jun 2026 15:08:00 -0400

si-local-file:///var/storage/secattach/20260610/26629499.html

Form 4 Emergent BioSolutions For: Jun 08 Filed by: LINDAHL RICHARD S

Wed, 10 Jun 2026 15:08:00 -0400

si-local-file:///var/storage/secattach/20260610/26629499.html

Form 4 Emergent BioSolutions For: Jun 08 Filed by: Glessner Coleen

Wed, 10 Jun 2026 15:07:00 -0400

si-local-file:///var/storage/secattach/20260610/26629494.html

Form 4 Emergent BioSolutions For: Jun 08 Filed by: Glessner Coleen

Wed, 10 Jun 2026 15:07:00 -0400

si-local-file:///var/storage/secattach/20260610/26629494.html

Form 4 Emergent BioSolutions For: Jun 08 Filed by: Hartzel William

Wed, 10 Jun 2026 15:06:00 -0400

si-local-file:///var/storage/secattach/20260610/26629489.html

Form 4 Emergent BioSolutions For: Jun 08 Filed by: Hartzel William

Wed, 10 Jun 2026 15:06:00 -0400

si-local-file:///var/storage/secattach/20260610/26629489.html

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Thu, 04 Jun 2026 08:02:00 -0400

Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources

GAITHERSBURG, Md., June 04, 2026 (GLOBE NEWSWIRE) -- In honor of National Naloxone Awareness Day on June 6^th, Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victoria’s Voice Foundation – which launched the awareness day with bipartisan congressional support – to spread awareness and encourage action against the ongoing opioid epidemic. Serving as a tribute to Victoria Siegel and all those lost to overdoses, Victoria’s Voice is continuing the "Shine. Wear. Share. Care." Campaign,

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Thu, 04 Jun 2026 08:02:00 -0400

Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources

Benchmark Reiterates Buy Rating on Emergent BioSolutions (EBS)

Tue, 02 Jun 2026 08:40:01 -0400

Benchmark analyst Robert Wasserman reiterated a Buy rating and $12.00 price target on Emergent BioSolutions (NYSE: EBS).

The analyst commented, "Emergent BioSolutions attended the 6th annual Benchmark Healthcare Conference and subsequently announced a $64.5 million contract award modification for its BAT botulism antitoxin from the US Government (HHS). Management presentations at the conference focused on the Company's ongoing efforts to meet the needs for Medical Countermeasure (MCM) products and NARCAN anti-opioid nasal spray, as well as expand the markets for existing products into new geographies and seek new opportunities for growth. We are maintaining our Buy rating on EBS shares and

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

Thu, 28 May 2026 16:01:00 -0400

GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT^® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT^®, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C,

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

Thu, 28 May 2026 16:01:00 -0400

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Wed, 20 May 2026 07:30:00 -0400

GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:

Goldman Sachs 11th Annual Leveraged Finance and Credit Conference, May 27-29
Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28
Jefferies Global Healthcare Conference, June 2-4
- June 3: presentation and webcast, 1:20-1:50 p.m. eastern time, register here.

Goldman Sachs 47th Annual Global Healthcare Conference, June 8-10

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Wed, 20 May 2026 07:30:00 -0400

GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:

Goldman Sachs 11th Annual Leveraged Finance and Credit Conference, May 27-29
Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28
Jefferies Global Healthcare Conference, June 2-4

June 3: presentation and webcast, 1:20-1:50 p.m. eastern time, register here.

Goldman Sachs 47th Annual Global Healthcare Conference, June 8-10

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Wed, 20 May 2026 07:30:00 -0400

GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:

Goldman Sachs 11th Annual Leveraged Finance and Credit Conference, May 27-29
Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28
Jefferies Global Healthcare Conference, June 2-4

June 3: presentation and webcast, 1:20-1:50 p.m. eastern time, register here.

Goldman Sachs 47th Annual Global Healthcare Conference, June 8-10

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Wed, 20 May 2026 07:30:00 -0400

GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:

Goldman Sachs 11th Annual Leveraged Finance and Credit Conference, May 27-29
Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28
Jefferies Global Healthcare Conference, June 2-4

June 3: presentation and webcast, 1:20-1:50 p.m. eastern time, register here.

Goldman Sachs 47th Annual Global Healthcare Conference, June 8-10

Emergent BioSolutions gets Saudi approval for smallpox, mpox vaccine

Mon, 18 May 2026 09:00:12 -0400

Emergent BioSolutions Inc (NYSE: EBS) received approval from the Saudi Food and Drug Authority for its ACAM2000 vaccine to prevent smallpox and mpox in high-risk individuals, according to a company statement.
The approval covers the smallpox and mpox vaccinia vaccine for people determined to be at high risk for infection from either disease. This marks the first Emergent product licensed by the Saudi regulatory authority.
The approval follows Singapore's Health Sciences Authority expanding ACAM2000's indication to include mpox prevention in high-risk adults. Emergent develops medical countermeasures for governments worldwide focused on biodefense preparedness.
The vaccine carries warnings for serious complications including myocarditis and

Emergent BioSolutions gets Saudi approval for smallpox, mpox vaccine

Mon, 18 May 2026 09:00:12 -0400

Emergent BioSolutions Inc (NYSE: EBS) received approval from the Saudi Food and Drug Authority for its ACAM2000 vaccine to prevent smallpox and mpox in high-risk individuals, according to a company statement.
The approval covers the smallpox and mpox vaccinia vaccine for people determined to be at high risk for infection from either disease. This marks the first Emergent product licensed by the Saudi regulatory authority.
The approval follows Singapore's Health Sciences Authority expanding ACAM2000's indication to include mpox prevention in high-risk adults. Emergent develops medical countermeasures for governments worldwide focused on biodefense preparedness.
The vaccine carries warnings for serious complications including myocarditis and

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

Mon, 18 May 2026 08:59:00 -0400

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. This follows Emergent’s recent announcement that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] to include prevention of mpox disease in adults determined to be

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

Mon, 18 May 2026 08:59:00 -0400

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. This follows Emergent’s recent announcement that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] to include prevention of mpox disease in adults determined to be

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

Mon, 18 May 2026 08:59:00 -0400

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. This follows Emergent’s recent announcement that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] to include prevention of mpox disease in adults determined to be

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

Mon, 18 May 2026 08:59:00 -0400

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. This follows Emergent’s recent announcement that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] to include prevention of mpox disease in adults determined to be

Form 4 Emergent BioSolutions For: Apr 30 Filed by: Dayal Sujata Tyagi

Mon, 04 May 2026 17:31:00 -0400
si-local-file:///var/storage/secattach/20260504/26427445.html

Form 4 Emergent BioSolutions For: Apr 30 Filed by: Dayal Sujata Tyagi

Mon, 04 May 2026 17:31:00 -0400
si-local-file:///var/storage/secattach/20260504/26427445.html